GHRP-6 and Ipamorelin side by side
GHRP-6 and Ipamorelin are both indexed under Growth hormone secretagogues. Every cell below carries the record it came from, and an axis with no retrieved value reads Unknown rather than being filled by inference.
Summary
Both act at the growth hormone secretagogue receptor, and the two are directly linked in the retrieved literature: a 1998 Journal of Medicinal Chemistry paper reports a series of growth hormone-releasing peptides derived from ipamorelin, and a 1998 European Journal of Endocrinology paper describes ipamorelin as the first selective growth hormone secretagogue.
[1, 2, 3]Side by side
| Axis | GHRP-6 | Ipamorelin |
|---|---|---|
| Reported mechanism | Acts through the growth hormone secretagogue receptor, the ghrelin receptor.[6] | A selective growth hormone secretagogue and ghrelin mimetic, acting at the growth hormone secretagogue receptor.[2, 12] |
| Molecular formula | C46H56N12O6[4] | C38H49N9O5[10] |
| Molecular weight | 873 g/mol[4] | 711.9 g/mol[10] |
| FDA application register | A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[5] | A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[11] |
Where the two literatures diverge
Selectivity is the divergence the retrieved titles support: ipamorelin is described as the first selective growth hormone secretagogue, while the GHRP-6 literature reports effects beyond growth hormone release, including gastroprokinetic effects compared against ghrelin and motilin in rats in a 2005 European Journal of Pharmacology paper. Neither compound returned an FDA application record. Half-life is unsourced for both in v1.
[1, 2, 3]Where this page sits
Full pages: GHRP-6 and Ipamorelin.
Shared class: Growth hormone secretagogues.
Other pairs in the same class
All side-by-side pages: index.
Sources
- A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. J Med Chem (1998). pmid:9733495
- Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol (1998). pmid:9849822
- Comparison of the gastroprokinetic effects of ghrelin, GHRP-6 and motilin in rats in vivo and in vitro. Eur J Pharmacol (2005). pmid:15890336
- PubChem Compound Summary for CID 4345065, Ghrp-6. PubChem, National Library of Medicine (2026). pubchem:4345065
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:ghrp-6
- Regulation of Pit-1 expression by ghrelin and GHRP-6 through the GH secretagogue receptor. Mol Endocrinol (2001). pmid:11518797
- Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. J Clin Endocrinol Metab (1993). pmid:8473389
- Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. J Clin Endocrinol Metab (1995). pmid:7883854
- The effects of ghrelin antagonists [D-Lys(3) ]-GHRP-6 or JMV2959 on ethanol, water, and food intake in C57BL/6J mice. Alcohol Clin Exp Res (2014). pmid:25257292
- PubChem Compound Summary for CID 9831659, Ipamorelin. PubChem, National Library of Medicine (2026). pubchem:9831659
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:ipamorelin
- Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther (2009). pmid:19289567
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis (2014). pmid:25331030
- Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. Drug Test Anal (2015). pmid:25869809
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.